Business Day Novo Nordisk falls 15% after obesity drug trial miss
Obesity drug CagriSema underperforms compared with Eli Lilly's tirzepatide in a trial
Obesity drug CagriSema underperforms compared with Eli Lilly's tirzepatide in a trial